ResearcherCentre Hospitalier Universitaire de BordeauxNo recent work listed

Mario Terlizzi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8496-6918; OpenAlex author ID A5044730023. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2021: 1 paper

Papers 1

Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery. Co-author DOI 10.1080/0284186x.2021.1944662 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Claudia Pouypoudat · 1 shared paper, 2021 · strength 0.11
- Paper Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to… DOI 10.1080/0284186x.2021.1944662 ↗
Jean‐Frédéric Blanc · 1 shared paper, 2021 · strength 0.11
- Paper Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to… DOI 10.1080/0284186x.2021.1944662 ↗
V. Vendrely · 1 shared paper, 2021 · strength 0.11
- Paper Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to… DOI 10.1080/0284186x.2021.1944662 ↗
Étienne Buscail · 1 shared paper, 2021 · strength 0.11
- Paper Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to… DOI 10.1080/0284186x.2021.1944662 ↗
Christophe Laurent · 1 shared paper, 2021 · strength 0.11
- Paper Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to… DOI 10.1080/0284186x.2021.1944662 ↗
L. Chiche · 1 shared paper, 2021 · strength 0.11
- Paper Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to… DOI 10.1080/0284186x.2021.1944662 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.